DE102020001811A1 - Preparation and pharmaceutical composition for use in medicine, in particular virology - Google Patents
Preparation and pharmaceutical composition for use in medicine, in particular virology Download PDFInfo
- Publication number
- DE102020001811A1 DE102020001811A1 DE102020001811.4A DE102020001811A DE102020001811A1 DE 102020001811 A1 DE102020001811 A1 DE 102020001811A1 DE 102020001811 A DE102020001811 A DE 102020001811A DE 102020001811 A1 DE102020001811 A1 DE 102020001811A1
- Authority
- DE
- Germany
- Prior art keywords
- preparation
- type
- pharmaceutical composition
- until
- killer
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/465—Hydrolases (3) acting on ester bonds (3.1), e.g. lipases, ribonucleases
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Virology (AREA)
- Molecular Biology (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Gastroenterology & Hepatology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- AIDS & HIV (AREA)
- Tropical Medicine & Parasitology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Beschrieben werden eine Zubereitung umfassend von in einer Lösung enthaltenen Killertoxinen wenigstens einer Art, Rhamnolipiden sowie Enzymen wenigstens einer Art. Ferner wird eine die Zubereitung umfassende pharmazeutische Zusammensetzung beschrieben, die in der Medizin und insbesondere in der Virologie zur Anwendung kommt.A preparation comprising killer toxins contained in a solution of at least one type, rhamnolipids and enzymes of at least one type is described. Furthermore, a pharmaceutical composition comprising the preparation is described, which is used in medicine and in particular in virology.
Description
Technisches GebietTechnical area
Die Erfindung bezieht sich auf eine Zubereitung sowie eine pharmazeutische Zusammensetzung zur Anwendung in der Medizin, insbesondere Virologie.The invention relates to a preparation and a pharmaceutical composition for use in medicine, in particular virology.
Stand der TechnikState of the art
Es ist bekannt, daß bestimmte Hefestämme während der exponentiellen Wachstumsphase einen für andere Hefestämmetoxischen Stoff in das Fermentationsmedium ausscheiden. Für derartige Hefestämme hat sich die Bezeichnung „Killerhefen“ durchgesetzt. Killerhefen scheiden während des Fermentationsprozesses Toxine aus, bei denen es sich in der Regel um kleine, hydrophobe Proteine handelt, gegen die die Killerhefen selbst immun sind, die aber während der Fermentation Kulturhefen abtöten. Die von den Killerhefen ausgeschiedenen Toxine werden im Hinblick auf die Bezeichnung „Killerhefe“ häufig auch als „Killertoxine“ bezeichnet.It is known that certain yeast strains excrete into the fermentation medium a substance which is toxic to other yeast strains during the exponential growth phase. The term “killer yeast” has established itself for such yeast strains. Killer yeasts excrete toxins during the fermentation process, which are usually small, hydrophobic proteins to which the killer yeasts themselves are immune, but which kill culture yeasts during fermentation. The toxins excreted by the killer yeast are often referred to as “killer toxins” with regard to the term “killer yeast”.
Es gibt bereits Untersuchungen, ob Killertoxine therapeutische Anwendbarkeit besitzen. So wird in Mycopathol. 96, 1986, 103--107die topische Anwendung von konzentriertem Killertoxin (Hansenula anomala UCSC 25F) bei Tieren beschrieben. Hierdurch sollte die mögliche Verwendung von Killertoxinen bei Hautpilzerkrankungen getestet werden. Ferner werden neben antimykotischen auch gewisse antibiotische Eigenschaften von Killertoxinen beschrieben.
Aus der Druckschrift
Darstellung der ErfindungPresentation of the invention
Der Erfindung liegt die Aufgabe zugrunde eine Zubereitungsform sowie eine pharmazeutische Zusammensetzung anzugeben, die in der Humanmedizin zur Anwendung kommen soll und insbesondere nach Verabreichung, vorzugsweise durch orale Einnahme, eine viralspezifische therapeutische Wirkung bei infizierten Menschen entfalten soll, vorzugsweise zur gezielten Bekämpfung von Coronaviren, covid-19, und/oder HIV.The invention is based on the object of specifying a preparation form and a pharmaceutical composition which is to be used in human medicine and, in particular, after administration, preferably by oral ingestion, is to develop a viral-specific therapeutic effect in infected people, preferably for the targeted control of coronaviruses, covid -19, and / or HIV.
Die Lösung der der Erfindung zugrundeliegenden Aufgabe ist im Anspruch 1 und 5 angegeben. Den Erfindungsgedanken in vorteilhafter Weise weiterbildende Merkmale sind in den Unteransprüchen sowie der weiteren Beschreibung beschrieben.The solution to the problem on which the invention is based is specified in claims 1 and 5. Features which advantageously develop the concept of the invention are described in the subclaims and in the further description.
Die lösungsgemäße Zubereitung umfasst in einer Lösung enthaltene Killertoxine wenigstens einer Art, Rhamnolipide sowie Enzyme wenigstens einer Art.The preparation according to the solution comprises killer toxins contained in a solution of at least one type, rhamnolipids and enzymes of at least one type.
Die wenigstens eine Art von Killertoxinen stellen vorzugsweise proapoptotischen Proteine dar oder besonders bevorzugt proapoptotische Proteine, die aus der Hefe Williopsis mrakii oder Hanseniaspora valbyensis gewonnen sind.The at least one type of killer toxins are preferably pro-apoptotic proteins or particularly preferably pro-apoptotic proteins obtained from the yeast Williopsis mrakii or Hanseniaspora valbyensis.
In besonderer Weise eignen sich proapoptotische Proteine, die aus folgender Gruppe von Proteinen auswählbar sind: K1, K2 und Glykoproteine von Williopsis mrakii oder Hanseniaspora valbyensis.Proapoptotic proteins that can be selected from the following group of proteins are particularly suitable: K1, K2 and glycoproteins from Williopsis mrakii or Hanseniaspora valbyensis.
Rhamnolipide sind als Biotenside bekannt und werden bspw. in der Kosmetik als Emulgatoren eingesetzt. Rhamnolipide werden durch Pseudomonas aeruginosa unter limitierenden Wachstumsbedingungen, bspw. durch Stickstoff- Phosphat- oder Eisenlimitierung, i.V.m. Ölen produziert.Rhamnolipids are known as biosurfactants and are used, for example, in cosmetics as emulsifiers. Rhamnolipids are produced by Pseudomonas aeruginosa under limiting growth conditions, e.g. by nitrogen, phosphate or iron limitation, in conjunction with oils.
Als bevorzugte Enzym eignen sich hydrolytische Enzyme, insbesondere RN-(ase).Hydrolytic enzymes, in particular RN- (ase), are suitable as preferred enzymes.
Das Enzym RN-(ase) vermag insbesondere das genetische Material des Coronavirus, d.h. ssRNA, nach Eintritt in eine viral infizierte Zelle zu spalten und zu zerstören.The enzyme RN- (ase) is particularly capable of cleaving and destroying the genetic material of the coronavirus, i.e. ssRNA, after entering a virally infected cell.
Die lösungsgemäße Zusammensetzung stellt somit eine pharmazeutisch anwendbare Zusammensetzung dar und dient der Medizin bevorzugt in der Humanmedizin und Virologie zur Bekämpfung von Coronaviren, insbesondere von covid-19, und/oder Humanen Immundefizienz-Viren (HIV).The composition according to the solution thus represents a pharmaceutically applicable composition and is used in medicine, preferably in human medicine and virology, to combat coronaviruses, in particular covid-19, and / or human immunodeficiency viruses (HIV).
Vorzugsweise wird die lösungsgemäße Zubereitung in einer wässrigen Lösung als flüssige Darreichungsform zur oralen Einnahme durch einen Menschen oder durch ein Tier zu- bzw. vorbereitet. Die Zubereitung erfolgt unter Verwendung nanobiotechnologischer Methoden, vorzugsweise betreffend die Herstellung und Handhabung des Enzyms RN-ase.The preparation according to the solution is preferably prepared or prepared in an aqueous solution as a liquid dosage form for oral ingestion by a human or by an animal. The preparation is carried out using nanobiotechnological methods, preferably relating to the production and handling of the enzyme RN-ase.
Über die Schleimhäute gelangen die Wirkstoffe in den Blutkreislauf des Patienten. Die Hülle von schädlichen Viren und/oder die Zellwände von mit Viren infizierter Wirtszellen wird durch das spezifische Killertoxin sowie durch Rhamnolipid aufgebrochen bzw. somit durchlässig, so dass das Enzym, RNA-ase, das genetische Material des Virus (ssRNA) vernichtet. Die Bestandteile des vernichteten Virus werden aus dem menschlichen oder tierischen Körper auf natürlichem Wege ausgeschieden.The active ingredients enter the patient's bloodstream through the mucous membranes. The shell of harmful viruses and / or the cell walls of host cells infected with viruses is broken up or thus permeable by the specific killer toxin and rhamnolipid, so that the enzyme, RNA-ase, destroys the genetic material of the virus (ssRNA). The components of the destroyed virus are excreted naturally from the human or animal body.
ZITATE ENTHALTEN IN DER BESCHREIBUNGQUOTES INCLUDED IN THE DESCRIPTION
Diese Liste der vom Anmelder aufgeführten Dokumente wurde automatisiert erzeugt und ist ausschließlich zur besseren Information des Lesers aufgenommen. Die Liste ist nicht Bestandteil der deutschen Patent- bzw. Gebrauchsmusteranmeldung. Das DPMA übernimmt keinerlei Haftung für etwaige Fehler oder Auslassungen.This list of the documents listed by the applicant was generated automatically and is included solely for the better information of the reader. The list is not part of the German patent or utility model application. The DPMA assumes no liability for any errors or omissions.
Zitierte PatentliteraturPatent literature cited
- DE 19912439 A1 [0004]DE 19912439 A1 [0004]
Zitierte Nicht-PatentliteraturNon-patent literature cited
- Mit Killertoxinen und ihren möglichen Verwendungen beschäftigen sich beispielsweise ClinicalMicrobiology Reviews, Juli 1997, 386/387, Critical Reviews in Microbiology, 18 (1), 1991, 47-87, The Journal of Immunology 1996, 1880-1885,Molecular Medicine, Volume 3, Nr. 8, August 1997, 544-552, JID Concise Communications, 177, 1988, 807-811, um nur einige zu nennen. In CriticalReviews in Microbiology, 18 (1), 1991,47-87 [0003]For example, ClinicalMicrobiology Reviews, July 1997, 386/387, Critical Reviews in Microbiology, 18 (1), 1991, 47-87, The Journal of Immunology 1996, 1880-1885, Molecular Medicine, Volume 3 deal with killer toxins and their possible uses , No. 8, August 1997, 544-552, JID Concise Communications, 177, 1988, 807-811 to name a few. In CriticalReviews in Microbiology, 18 (1), 1991, 47-87 [0003]
Claims (8)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE102020001811.4A DE102020001811A1 (en) | 2020-03-19 | 2020-03-19 | Preparation and pharmaceutical composition for use in medicine, in particular virology |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE102020001811.4A DE102020001811A1 (en) | 2020-03-19 | 2020-03-19 | Preparation and pharmaceutical composition for use in medicine, in particular virology |
Publications (1)
Publication Number | Publication Date |
---|---|
DE102020001811A1 true DE102020001811A1 (en) | 2021-09-23 |
Family
ID=77552681
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DE102020001811.4A Ceased DE102020001811A1 (en) | 2020-03-19 | 2020-03-19 | Preparation and pharmaceutical composition for use in medicine, in particular virology |
Country Status (1)
Country | Link |
---|---|
DE (1) | DE102020001811A1 (en) |
Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1994016061A1 (en) | 1993-01-15 | 1994-07-21 | Micro Vesicular Systems, Inc. | Method of inhibiting viral reproduction |
DE19912439A1 (en) | 1999-03-19 | 2000-09-28 | Inropharm Vet Pharm Produkte G | Use of yeast-derived killer toxins to treat or prevent diarrhea, particularly in piglets and especially where caused by Escherichia coli |
US20040180094A1 (en) | 2003-03-11 | 2004-09-16 | Hemolytics, Inc. | Activation agents on the surface of encapsulation vesicles |
US20070014778A1 (en) | 2005-06-06 | 2007-01-18 | Chow Lee | Endoribonuclease and uses thereof |
WO2018208530A1 (en) | 2017-05-07 | 2018-11-15 | Locus Ip Company, Llc | Cosmetic compositions for skin health and methods of using same |
WO2019168852A1 (en) | 2018-02-28 | 2019-09-06 | Locus Agriculture Ip Company, Llc | Microbe-based products for controlling fusarium infections in plants and agricultural products |
-
2020
- 2020-03-19 DE DE102020001811.4A patent/DE102020001811A1/en not_active Ceased
Patent Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1994016061A1 (en) | 1993-01-15 | 1994-07-21 | Micro Vesicular Systems, Inc. | Method of inhibiting viral reproduction |
DE19912439A1 (en) | 1999-03-19 | 2000-09-28 | Inropharm Vet Pharm Produkte G | Use of yeast-derived killer toxins to treat or prevent diarrhea, particularly in piglets and especially where caused by Escherichia coli |
US20040180094A1 (en) | 2003-03-11 | 2004-09-16 | Hemolytics, Inc. | Activation agents on the surface of encapsulation vesicles |
US20070014778A1 (en) | 2005-06-06 | 2007-01-18 | Chow Lee | Endoribonuclease and uses thereof |
WO2018208530A1 (en) | 2017-05-07 | 2018-11-15 | Locus Ip Company, Llc | Cosmetic compositions for skin health and methods of using same |
WO2019168852A1 (en) | 2018-02-28 | 2019-09-06 | Locus Agriculture Ip Company, Llc | Microbe-based products for controlling fusarium infections in plants and agricultural products |
Non-Patent Citations (1)
Title |
---|
Mit Killertoxinen und ihren möglichen Verwendungen beschäftigen sich beispielsweise ClinicalMicrobiology Reviews, Juli 1997, 386/387, Critical Reviews in Microbiology, 18 (1), 1991, 47-87, The Journal of Immunology 1996, 1880-1885,Molecular Medicine, Volume 3, Nr. 8, August 1997, 544-552, JID Concise Communications, 177, 1988, 807-811, um nur einige zu nennen. In CriticalReviews in Microbiology, 18 (1), 1991,47-87 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DE69535519T2 (en) | ON YEAST BASED VEHICLES FOR DELIVERY | |
DE69837348T2 (en) | PROCESS FOR INACTIVATING BACTERIA CONTAINING BACTERIA SPORES | |
Rosberger et al. | Successful treatment of microsporidial keratoconjunctivitis with topical fumagillin in a patient with AIDS | |
MarieáMakabenta | Nanotherapeutics using all-natural materials. Effective treatment of wound biofilm infections using crosslinked nanoemulsions | |
Evans et al. | Short‐duration therapy with terbinafine 1% cream in dermatophyte skin infections | |
EP2385835A1 (en) | Use of deuterium oxide for treating viral diseases of the eye | |
Halteh et al. | Over-the-counter and natural remedies for onychomycosis: do they really work | |
Tonon et al. | Interactions between Terpinen-4-ol and Nystatin on biofilm of Candida albicans and Candida tropicalis | |
DE102020001811A1 (en) | Preparation and pharmaceutical composition for use in medicine, in particular virology | |
DE69433789T2 (en) | METHODS OF INHIBITION OF HIV-ASSAYED DISEASE BY MONOCLONAL ANTIBODY AGAINST SELF-TESTED CYTOTOXIC T CELLS | |
Azeiz et al. | Efficacy of thymoquinone against vaginal candidiasis in prednisolone-induced immunosuppressed mice | |
DE19961141A1 (en) | Pharmaceutical composition of spider venoms and their preparation and use for the treatment of tumor diseases | |
EP0421022B1 (en) | Use of catabolic enzymes to combat a first hiv infection | |
KINGERY et al. | Certain volatile oils and stearoptens as fungicides: an experimental study | |
DE102021104798A1 (en) | Preparation and pharmaceutical composition for use in medicine, in particular virology | |
DE60213785T2 (en) | SAPONIN INACTIVATED MYCOPLASMIC VACCINES | |
DE102006011747A1 (en) | Dermatological or cosmetic preparation, useful to prevent and/or treat skin allergy, comprises a compound e.g. 3'-methoxy-4'-nitroflavone, which modulates the immunological function of the langerhans cell in skin, and carrier | |
EP1096942B1 (en) | Use of a medicine containing a quantity of tyrothricine for the treatment of viral infections | |
EP0702955B1 (en) | Use of BK-RiV preparations as a drug for AIDS therapy | |
DE19828596A1 (en) | Use of polyvalent bacteriophages | |
EP0587002A1 (en) | Preservative agent containing thymol and/or carvacrol for injectable formulations | |
DE102007014752A1 (en) | Interleukin for use with human identical amino acid sequence and glycosyl residue for use as therapeutic agent for bacterial infections, sepsis, mycoplasma disease, autoimmune disease and multiple sclerosis in humans and animals | |
DE739594C (en) | Process for the production of a healing and protective serum against distemper | |
WO2007053874A1 (en) | Use of propolis for producing a medicament | |
DE501693C (en) | Process for the manufacture of anti-tuberculosis drugs and medicines |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
R012 | Request for examination validly filed | ||
R002 | Refusal decision in examination/registration proceedings | ||
R003 | Refusal decision now final |